BioSpace News Archive

Can-Fite BioPharma Ltd. announced the Company’s CEO, Dr. Pnina Fishman, will deliver a presentation titled “Piclidenoson for the Treatment of Psoriasis: Clinical Development and Mechanism of Drug Action” at the 3rd Annual Dermatology Drug Development Summit to leading European pharma and biotech industry stakeholders on April 6, 2022 at 4:30 pm in Frankfurt, Germany.

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year ended December 31, 2021 and provided a corporate update.

Better Therapeutics, Inc today announced its financial results for the fourth quarter and full year ending December 31, 2021.

Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.

Provention Bio, Inc. today announced positive results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all key CVB strains associated with type 1 diabetes (T1D) autoimmunity.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2022.

HAPPE Spine announces strategic new additions to its Board of Directors.

Actuate Therapeutics, Inc. announced today two poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, presented a clinical update from the ongoing Phase 1 trial of INB-100.